The microemulsion formulation of cyclosporine (Neoral®) represents a major advance in treatment, improving pharmacokinetics and permitting a more rational strategy for the administration and monitoring of therapy. Neoral consistently increases C(max) and AUC while decreasing T(max). The long-term benefits of this preparation in the rapidly-changing environment of renal transplantation immunosuppression are being studied. Optimal immunosuppressive treatment continues to evolve, with potential future roles for such newer developments as tacrolimus and a less costly genetic form of conventional cyclosporine.
|Original language||English (US)|
|Number of pages||14|
|Journal||Today's Therapeutic Trends|
|State||Published - 1998|
ASJC Scopus subject areas
- Pharmacology (medical)